Recombinant human thrombopoietin safety and efficacy in pediatric allogeneic hematopoietic stem cell transplantation: A cohort study

Table 1 Characteristics of hematologic diseases patients in different age groups, n (%)

Variables	Total (n = 79)	0- to 9-year-old group (n = 36)	10- to 17-year-old group (n = 43)	P value
Age, years, median (range)	10 (4-16)	8 (4-9)	12 (10-16)	< 0.001
Disease diagnosis				0.307
Fanconi anemia	8 (10.1)	3 (8.3)	5 (11.6)
Aplastic anemia	50 (63.3)	27 (75.0)	23 (53.5)
Leukemia	19 (24.1)	6 (16.7)	13 (30.2)
T-cell lymphoblastic lymphoma	1 (1.3)	0	1 (2.3)
Platelet dysfunction	1 (1.3)	0	1 (2.3)
Sex				0.210
Male	39 (49.4)	15 (41.7)	24 (55.8)
Female	40 (50.6)	21 (58.3)	19 (44.2)
BMI, kg/m2, median (range)	16.5 (12.3-26.3)	15.6 (12.3-22.3)	17.1 (12.7-26.3)	0.004
Transplantation type				0.771
MSD-HSCT	21 (26.6)	9 (25.0)	12 (27.9)
Haplo-HSCT	58 (73.4)	27 (75.0)	31 (72.1)
Donor type				0.076
Siblings	50 (63.3)	19 (52.8)	31 (72.1)
Parents	29 (36.7)	17 (47.2)	12 (27.9)
Donor-recipient sex				0.477
Male to male	29 (36.7)	11 (30.6)	18 (41.9)
Male to female	32 (40.5)	18 (50.0)	14 (32.6)
Female to female	8 (10.1)	3 (8.3)	5 (11.6)
Female to male	10 (12.7)	4 (11.1)	6 (14.0)
HLA-matched				0.352
3/6	20 (25.3)	10 (27.8)	10 (23.3)
5/10	33 (41.8)	15 (41.7)	18 (41.9)
6/10	3 (3.8)	0	3 (7.0)
7/10	1 (1.3)	1 (2.8)	0
6/6	5 (6.3)	1 (2.8)	4 (9.3)
10/10	17 (21.5)	9 (25.0)	8 (18.6)
Mononuclear cell count, 108/kg, median (range)	15.9 (7.0-32.9)	17.0 (7.6-32.9)	14.3 (7.0-29.9)	0.251
CD34+ cell count, 106/kg, median (range)	6.2 (2.0-33.3)	7.3 (2.6-19.7)	5.1 (2.0-33.3)	0.071

BMI: Body mass index; Haplo-HSCT: Haploidentical-hematopoietic stem cell transplantation; HLA: Human leukocyte antigen; MSD-HSCT: Matched sibling donor-hematopoietic stem cell transplantation.

Table 2 Neutrophil and platelet implantation of hematologic diseases in patients in different age groups

Variables	Total (n = 79)	0- to 9-year-old group (n = 36)	10- to 17-year-old group (n = 43)	P value
Time to neutrophil engraftment, day, median (range)	12 (10-32)	12 (10-20)	12 (10-32)	0.082
Time to platelet engraftment, day, median (range)	16 (11-41)	14 (11-24)	16 (11-41)	0.017
Platelet transfusions, U, median (range)	14 (4-71)	13 (5-40)	15 (4-71)	0.057
Time to platelet recovery, day, median (range)
≥ 20 × 109/L	9 (2-23)	10 (2-20)	9 (4-23)	0.942
≥ 50 × 109/L	11 (2-34)	11 (2-20)	12 (5-34)	0.351
≥ 100 × 109/L	16 (3-88)	16 (3-88)	18 (5-76)	0.037
DPE, n (%)	2 (4.0)	0	5 (11.6)	0.059
SFPR, n (%)	0	0	0

DPE: Delayed platelet engraftment; SFPR: Secondary failure of platelet recovery.

Table 3 Transplantation-related complications of hematologic diseases in patients in different age groups, n (%)

Variables	Total (n = 79)	0- to 9-year-old group (n = 36)	10- to 17-year-old group (n = 43)	P value
aGVHD	42 (53.2)	22 (61.1)	20 (46.5)	0.195
I	16 (20.3)	11 (30.6)	5 (11.6)	0.1001
II	11 (13.9)	4 (11.1)	7 (16.3)
III	10 (12.7)	5 (13.9)	5 (11.6)
IV	5 (6.3)	2 (5.6)	3 (7.0)
cGVHD	8 (10.1)	3 (8.3)	5 (11.6)	0.721
Virus reactivation
CMV	22 (27.8)	11 (30.6)	11 (25.6)	0.623
EBV	4 (5.1)	3 (8.3)	1 (2.3)	0.326

¹The difference of I and II-IV between the two groups.

aGVHD: Acute graft-vs-host disease; cGVHD: Chronic graft-vs-host disease; CMV: Cytomegalovirus; EBV: Epstein-Barr virus.

Table 4 Bleeding for hematologic diseases patients after recombinant human thrombopoietin treatment in different age groups, n (%)

Variables	Total (n = 79)	0- to 9-year-old group (n = 36)	10- to 17-year-old group (n = 43)	P value
Bleeding	16 (20.3)	7 (19.4)	9 (20.9)	0.870
Bleeding sites				0.891
Gastrointestinal tract	10 (12.7)	5 (13.9)	5 (11.6)
Bladder	3 (3.8)	1 (2. 8)	2 (4.7)
Mucosal and skin	1 (1.3)	0	1 (2.3)
Multiple sites	2 (2.5)	1 (2. 8)	1 (2.3)

rhTPO: Recombinant human thrombopoietin.